AstraZeneca (AZN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncology/Respiratorysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.14% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life
- Carterra Advances Lab-In-The-Loop Drug Discovery Through New Scientific Collaboration
- AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square
- Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results
- Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
- Multiply Labs Raises $75 Million Series B to Close the Gap Between Drug Discovery and Drug Manufacturing
- Citi raises AstraZeneca target to £186 as tozorakimab prospects improve
- AstraZeneca opens new R&D centre in Cambridge, US
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for AstraZeneca.
Full AZN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.